SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., traded under ticker BCYP, is a clinical-stage biopharmaceutical company that reached the public markets through its de-SPAC merger with Big Cypress Acquisition Corp, a blank-check vehicle that completed its IPO in 2021. Big Cypress Acquisition Corp was sponsored by Big Cypress Holdings LLC and targeted the healthcare and life sciences sector. SAB Biotherapeutics focuses on developing human polyclonal antibody therapeutics using a proprietary transgenic cattle platform. The company filed an 8-K current report with the SEC on September 26, 2025, accession number 0001193125-25-220721, reflecting a post-merger operating entity. Sign up at SpacDesk for full filing history, SPAC deal analytics, and real-time alerts on BCYP and hundreds of other de-SPAC companies.